NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
09/12/2023
Back to search
Official data from USPTO
THERORNA
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
22
Latest update
09/12/2023
Trademark type
Combined
Nice classes
5
Filing date
06/25/2021
Registration date
09/12/2023
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
09/12/2023
Last transaction
09/12/2023
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Foreign priority
Drawing code
5
Owner type
99
Owner location
Haidian Dist., Beijing, CN
Examiner
CALIENDO, COURTNEY
Law office
O20
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
THERORNA Inc
Representatives
Paulo A. de Almeida PATEL & ALMEIDA, P. C.
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical preparations for human biomedicinepharmaceutical preparations used for protein replacement therapycardiovascular therapyliver disease therapycancer therapyrespiratory disease therapyinfectious disease therapyneurological disease therapyfor use as a new coronavirus vaccine; vaccines; drugs for medical purposesmedicinal preparations used for protein replacement therapycardiovascular therapyliver disease therapycancer therapyrespiratory disease therapyinfectious disease therapyneurological disease therapyfor use as a new coronavirus vaccine; opotherapy preparations; serotherapeutic medicinesmedical immune serums used for protein replacement therapycardiovascular therapyliver disease therapycancer therapyrespiratory disease therapyinfectious disease therapyneurological disease therapyfor use as a new coronavirus vaccine; biological preparations for medical purposesbiological preparations used for protein replacement therapycardiovascular therapyliver disease therapycancer therapyrespiratory disease therapyinfectious disease therapyneurological disease therapyfor use as a new coronavirus vaccine; medicines for human purposesmedicines used for protein replacement therapycardiovascular therapyliver disease therapycancer therapyrespiratory disease therapyinfectious disease therapyneurological disease therapynew coronavirus vaccine; chemical preparations for medical purposesmedicinal preparations used for protein replacement therapycardiovascular therapyliver disease therapycancer therapyrespiratory disease therapyinfectious disease therapyneurological disease therapynew coronavirus vaccine; adjuvants for medical purposes; Blood for medical purposes; nutraceutical preparations for therapeutic or medical purposes; immunostimulants; Medical cell function activating drugsmedicinal preparations used for protein replacement therapycardiovascular therapyliver disease therapycancer therapyrespiratory disease therapyinfectious disease therapyneurological disease therapyfor use as a new coronavirus vaccine; Pharmaceutical preparations for the treatment of immune system related diseases and disorders; tumor suppressing agents; Anti-sarcoma preparations; cytostatics for medical purposes; Pharmaceutical products for the prevention and treatment of cancer; all the foregoing using circular ribonucleic acid (RNA)
Publications
History of USPTO decisions and trademark events.
22 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
09/12/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
06/27/2023
PUBO
PUBLISHED FOR OPPOSITION
06/27/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
06/07/2023
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
05/19/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
05/12/2023
XAEC
EXAMINER'S AMENDMENT ENTERED
05/12/2023
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
05/12/2023
GNEA
EXAMINERS AMENDMENT E-MAILED
05/12/2023
CNEA
EXAMINERS AMENDMENT -WRITTEN
05/12/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
11/01/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
11/01/2022
ALIE
ASSIGNED TO LIE
11/01/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
09/19/2022
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
09/19/2022
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
03/18/2022
GNRT
NON-FINAL ACTION E-MAILED
03/18/2022
CNRT
NON-FINAL ACTION WRITTEN
03/18/2022
DOCK
ASSIGNED TO EXAMINER
03/16/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
09/09/2021
NWAP
NEW APPLICATION ENTERED
06/29/2021
Continuous trademark protection
Get notified about every new filing that threatens THERORNA or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.